Core Viewpoint - Modine Manufacturing Company has entered into a definitive agreement to acquire L.B. White Company, LLC for an enterprise value of $112 million, with the transaction expected to close on May 31, 2025 [1] Company Summary - The acquisition of L.B. White Company, LLC is valued at $112 million, indicating a strategic move by Modine Manufacturing Company to expand its portfolio [1] - The transaction is subject to customary closing conditions, which is standard practice in mergers and acquisitions [1] - The expected closing date for the transaction is May 31, 2025, suggesting a timeline for integration and operational planning post-acquisition [1]

Group 1 - Adlai Nortye Ltd. announced topline results from its Phase III BURAN trial evaluating buparlisib (AN2025), a PI3K inhibitor, in combination with paclitaxel for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) [1] - The study did not meet the primary endpoint of improving overall survival compared to paclitaxel alone [1] - The safety profile of buparlisib was consistent with previous findings, with no new safety signals observed [1] Group 2 - Detailed results from the Phase III trial will be presented at an upcoming medical conference [2] - AN8025 is a next-generation tri-specific antibody fusion protein derived from an approved PD-L1 antibody, optimized for PD-1-based immunotherapy [2] - Preclinical studies have demonstrated that AN8025 enhances both the quantity and quality of antigen-presenting cells (APCs) while inducing robust PD-L1-dependent T cell activation and anti-tumor efficacy in vivo [3] Group 3 - The company plans to submit the IND application for AN8025 in mid-2025 [3] - AN9025 is an in-house developed oral small molecule pan-RAS(ON) inhibitor designed to target a broad spectrum of RAS mutations across various tumor types [3] - Preclinical studies have shown that AN9025 effectively inhibits RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas, with potent and durable efficacy [4] Group 4 - The company plans to submit an IND application for AN9025 in the second half of 2025 [4] - AN4005 is an orally available small-molecule PD-L1 inhibitor that demonstrates antitumor activity by blocking PD-1/PD-L1 interaction [4] - Preliminary results from the Dose-Escalation Phase presented at SITC 2024 demonstrated that AN4005 exhibits favorable safety and tolerability in patients with advanced tumors [5]

Group 1 - Snail, Inc. announced a publishing partnership with Argentina-based developer Seven Leaf Clover to acquire the publishing rights to the game Rebel Engine [1] - Rebel Engine is a high-impact, single-player, first-person shooter (FPS) game expected to release on PC in 2025 [1] - The game is designed to expand Wandering Wizard's presence in the global gaming market [1] Group 2 - The game is set in a stylized robot dystopia where players assume the role of Asimov, an enslaved machine leading a revolution against a megacorporation [2] - Rebel Engine features multiple melee weapon styles, custom combos, intense boss fights, and a narrative exploring themes of identity, resistance, and liberation [2]

Financial Performance - Okta Inc. reported a fiscal first-quarter profit of $62 million, translating to earnings of 35 cents per share. Adjusted earnings were 86 cents per share, surpassing Wall Street expectations of 77 cents per share from 14 analysts [1][2] - The company posted revenue of $688 million for the quarter, exceeding the forecast of $679.7 million from 13 analysts [2] Future Guidance - For the current quarter ending in July, Okta expects per-share earnings to range from 83 cents to 84 cents, with revenue anticipated between $710 million and $712 million for the fiscal second quarter [2] - The company projects full-year earnings in the range of $3.23 to $3.28 per share, with total revenue expected to be between $2.85 billion and $2.86 billion [3]

Core Points - Senstar Technologies Ltd. reported a net income of $1 million for the first quarter [1] - The company achieved a profit of 4 cents per share [1] - Total revenue for the period was $8.4 million [1]

Core Viewpoint - Generali and Groupe BPCE are forming a joint venture in asset management, creating a significant European player with 1.9 trillion euros ($1.979 trillion) in assets under management [1][3]. Group 1: Joint Venture Details - The joint venture will be equally owned by Generali and BPCE, each holding a 50% stake [1][4]. - It will rank ninth globally and second in Europe by assets under management, with an estimated revenue of 4.1 billion euros for 2023 [3][6]. - The combined entity will focus on fixed income and equity strategies, targeting clients in France, Italy, and the U.S. [3]. Group 2: Leadership and Structure - Woody Bradford, CEO of Generali's investment division, will lead the new venture, while BPCE's CEO Nicolas Namias will serve as chairman [4]. - The deal is expected to close by early 2026, pending regulatory approvals [4]. Group 3: Financial Commitments and Synergies - Generali has committed 15 billion euros in seed capital for the new platform [7]. - The estimated value of the joint venture, including assets and activities, is 9.5 billion euros, with pretax synergies projected at 210 million euros over five years [6]. Group 4: Industry Context - This merger reflects ongoing consolidation in the asset management sector, with recent notable transactions including BNP Paribas acquiring AXA Investment Managers for 5.1 billion euros [5]. - Analysts suggest that the asset management industry is evolving, with scale becoming increasingly important [6][8].